Pharmacodynamics +<unk>  Site Ki (nM) ' 273.5 ' 13.4 >10,000 5-HT1A >10,000 5-HT1B >10,000 5-HT1D >10,000 5-HT2A >10,000 5-HT2C 457 α1A 11,900 α2A >10,000 D2 >10,000 D3 >10,000 H1 312 6,700<unk>  is a fairly selective norepinephrine reuptake inhibitor (NRI), with approximately 20-fold selectivity for the norepinephrine transporter (NET) over the serotonin transporter (SERT). Despite this selectivity,<unk>  does slightly inhibit the reuptake of serotonin at therapeutic doses. It does not interact with or inhibit the dopamine transporter (DAT).<unk>  has been found to inhibit both brain and cardiac GIRKs, a characteristic it shares with the NRI atomoxetine. Pharmacokinetics Both the (R,R)-(–) and (S,S)-(+)-enantiomers of<unk>  are predominantly metabolized by the CYP3A4 isoenzyme. The primary metabolite of<unk>  is O-desethylreboxetine, and there are also three minor metabolites—Phenol A, Phenol B, and UK1, Phenol B being the most minor.
Reboxetine
Fluoxetine
Dapoxetine
Duloxetine
Paroxetine
Atomoxetine
Nabilone
Vinpocetine